A company-building system for regulated biomedical innovation.
Biomedical ventures require more than promising science. They require a coherent architecture linking the product, evidence, regulation, manufacturing, ownership, capital and market. Logos Bioscience creates that architecture.
We do not simply support ventures. We architect them.
Logos Bioscience combines scientific conviction with disciplined company building. We define the product, structure the asset, establish its regulatory and manufacturing pathway, assemble the required partners and create the corporate vehicle needed to advance it.
The Model
One architecture. Five critical stages.
Central Question
Is there a differentiated opportunity worth building?
Key Activities
- Scientific and technical assessment
- Unmet-need analysis
- Translational relevance
- Competitive landscape
- Initial intellectual-property assessment
- Market and adoption logic
- Strategic-fit assessment
Output
An evidence-based opportunity thesis.
Risks Reduced
- Weak differentiation
- Unclear clinical need
- Poor commercial logic
- Lack of defensibility
- Inadequate strategic fit
Value is designed, not added at the end.
Logos structures each venture to retain and compound value through equity, intellectual property, data, know-how, licensing rights, royalties, territorial rights and strategic control. The goal is not simply to complete a project. The goal is to build an asset capable of producing long-term biomedical and economic value.
The architecture begins with the opportunity.
We work with scientists, technology owners, institutions, manufacturers and investors prepared to build with discipline.